Labiotech.eu

Top 5 Things to Know About Immunotherapies – A Review

Immunotherapy – A big word with much meaning. There’s no use in talking about their history. The fact that immunotherapies seem to be the next big thing in biotech is reason enough to discuss them. For this purpose, we have caught up with Etienne Drouet, Vice President of Strategic Development at SynteractHCR, an international CRO. […]

November 13, 2017 - 13 minutesmins - By Larissa Warneck-Silvestrin

News and Trends 10 Nov 2017

Roche Partners with French Startup to Diagnose Septic Shock

In its first partnership with a biotech startup, Roche Diagnostics will help develop a blood test to accompany Inotrem’s experimental therapy for septic shock. Roche Diagnostics has announced a research collaboration with Inotrem, a biotech startup based in Nancy, France. The deal, for which the amount was undisclosed, concerns the development of a companion diagnostic test […]

November 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Evotec CEO Werner Lanthaler Biotech Innovation Partnerships

Interview 9 Nov 2017

Interview with Europe’s Leader in Biotech Partnerships

I talked with Werner Lanthaler, CEO of Evotec, during Bio Europe 2017 to ask him what the key is to his company’s great success in supporting biotech innovation and establishing strategic partnerships. Evotec started off as a contract research organization in Hamburg back in 1993. Today it has over 2,000 employees worldwide, its own pipeline […]

November 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 9 Nov 2017

Doctors Use Genetically Modified Stem Cells to Give a Boy New Skin

The ‘butterfly child’ who lost 80% of his skin has been successfully treated. The boy is now able to go to school and enjoy life with family and friends. A medical team from the Ruhr-Universität Bochum’s burn unit and the Center for Regenerative Medicine at the University of Modena have treated a boy suffering from […]

November 9, 2017 - 3 minutesmins - By Alex Dale

neurimmune ono pharmaceutical neurodegenerative disease

More News! 9 Nov 2017

Swiss Biotech and Japanese Pharma Team Up to Tackle Neurodegenerative Disease

Neurimmune and Ono Pharmaceutical have partnered to develop an antibody drug against a still undisclosed neurodegenerative disease. Neurimmune has a new partner to help it develop treatments for neurodegenerative diseases. Ono Pharmaceutical will work together with the Swiss biotech to develop human antibodies against a new disease target that remains undisclosed for now. In exchange for an […]

November 9, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Interview 9 Nov 2017

Meet the Spin-Out Queen Taking on Neurological Diseases

Mary Kerr, CEO of NeRRe and Managing Director of KanDy, told us how its approaches could change the face of therapies for neuronal hypersensitivity and women’s health indications. Mary Kerr’s career has taken her through the rigorous world of big pharma, which she says gave her “the skillset… the development, the exposure and the opportunity to work […]

November 9, 2017 - 4 minutesmins - By Alex Dale

Interview 8 Nov 2017

Interviewing Europe’s Most Intense Investor about Trends in Biotech

I interviewed Kate Bingham of SV Health Investors about Alzheimer’s, checkpoint inhibitors, gender diversity and more at BIO Europe. BIO Europe 2017 was off to a racing start on Monday morning when I chatted with Kate Bingham, Managing Partner of SV Health Investors, formerly SV Life Sciences. Since she joined the firm in 1991, she […]

November 8, 2017 - 6 minutesmins - By Evelyn Warner

News and Trends 8 Nov 2017

German Pharma and Biotech Gang Up on NASH in an Exciting Collaboration

Boehringer Ingelheim’s fight against liver disease is taking shape, having agreed on a partnership with RNA pioneer MiNA Therapeutics to fight NASH. British biotech, MiNA Therapeutics, has announced a partnership with pharma giant Boehringer Ingelheim to focus on developing compounds to treat fibrotic liver diseases like Non-Alcoholic SteatoHepatitis (NASH). Bringing MiNA on board has given Boehringer Ingelheim access to […]

November 8, 2017 - 3 minutesmins - By Alex Dale

News and Trends 8 Nov 2017

German Biotech Aims for $100M IPO to Support Anti-Inflammatory Drug Development

InflaRx has announced that its shares will cost $15 when they’re launched for the company’s IPO, which could bring in over $100M for the biotech. InflaRx focuses on developing monoclonal antibodies targeted towards the complement system to treat potentially fatal inflammatory diseases. The company that its share will cost $15 (€13) when the company launches its IPO, […]

November 8, 2017 - 2 minutesmins - By Alex Dale

News and Trends 8 Nov 2017

Phase I Results are in for Swedish Biotech’s Cancer Antibody

Alligator Bioscience has reported promising results from a Phase I study, where its candidate has been well tolerated in patients with late-stage solid tumors. Alligator Bioscience, located in Lund, Sweden, develops antibody-based immunotherapies to fight cancer. Its pipeline includes clinical and pre-clinical drug candidates, including ADC-1013 and ATOR-1015, as well as novel research candidates. The company […]

November 8, 2017 - 3 minutesmins - By Alex Dale

neurological disorders memory blocking uk

News and Trends 7 Nov 2017

British Researchers Find Thought Police to Treat Neurological Disorders

Cambridge University scientists have identified a chemical in the brain that blocks unwanted thoughts, offering a new avenue to treat neurological disorders. Researchers at the University of Cambridge have found identified a new process in the brain’s prefrontal cortex that can block our thoughts. The research, published in Nature Communications, demonstrated that the ability to block unwanted thoughts […]

November 7, 2017 - 3 minutesmins - By Alex Dale

News and Trends 6 Nov 2017

Austrian Biotech’s Vaccine Against Tropical Virus Moves Nicely Through Phase II

Chikungunya fever could be the next big global outbreak. Reassuringly, Themis’ vaccine has so far performed well in a Phase II study. Vienna-based biotech, Themis, develops urgently needed vaccines against diseases, which have the potential to be the next global outbreak. The company has announced encouraging preliminary Phase II results for its vaccine against chikungunya […]

November 6, 2017 - 3 minutesmins - By Alex Dale

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Top 5 Things to Know About Immunotherapies – A Review

Roche Partners with French Startup to Diagnose Septic Shock

Interview with Europe’s Leader in Biotech Partnerships

Doctors Use Genetically Modified Stem Cells to Give a Boy New Skin

Swiss Biotech and Japanese Pharma Team Up to Tackle Neurodegenerative Disease

Meet the Spin-Out Queen Taking on Neurological Diseases

Interviewing Europe’s Most Intense Investor about Trends in Biotech

German Pharma and Biotech Gang Up on NASH in an Exciting Collaboration

German Biotech Aims for $100M IPO to Support Anti-Inflammatory Drug Development

Phase I Results are in for Swedish Biotech’s Cancer Antibody

British Researchers Find Thought Police to Treat Neurological Disorders

Austrian Biotech’s Vaccine Against Tropical Virus Moves Nicely Through Phase II

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!